Per Magnus Humpert
Research Subjects
Research Interests
Per Magnus Humpert has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
A. Bierhaus
3 shared publicationsDimitrios Oikonomou
Stoffwechselzentrum Rhein-Pfalz, Mannheim, Germany
3 shared publicationsM. Morcos
3 shared publicationsMichael Morcos
Stoffwechselzentrum Rhein-Pfalz, Mannheim, Germany
3 shared publications- Andrea Schlotterer
5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, D-68167 Mannheim, Germany
2 shared publications Angelika Bierhaus
Medizinische Klinik 1 und Klinische Chemie, University Hospital, Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
- 14 January 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 160
Protective Effects of Transient Glucose Exposure in Adult C. elegans
C. elegans are used to study molecular pathways, linking high glucose levels (HG) to diabetic complications. Persistent exposure of C. elegans to a HG environment induces the mitochondrial formation of reactive oxygen species (ROS) and advanced glycation endproducts (AGEs), leading to neuronal damage and decreased lifespan. Studies suggest that transient high glucose exposure (TGE) exerts different effects than persistent exposure. Thus, the effects of TGE on ROS, AGE-formation and life span were studied in C. elegans. Four-day TGE (400 mM) as compared to controls (0mM) showed a persistent increase of ROS (4-days 286 ± 40 RLUs vs. control 187 ± 23 RLUs) without increased formation of AGEs. TGE increased body motility (1-day 0.14 ± 0.02; 4-days 0.15 ± 0.01; 6-days 0.16 ± 0.02 vs. control 0.10 ± 0.02 in mm/s), and bending angle (1-day 17.7 ± 1.55; 3-days 18.7 ± 1.39; 6-days 20.3 ± 0.61 vs. control 15.3 ± 1.63 in degree/s) as signs of neuronal damage. Lifespan was increased by 27% (21 ± 2.4 days) after one-day TGE, 34% (22 ± 1.2 days) after four-days TGE, and 26% (21 ± 1.4 days) after six-days TGE vs. control (16 ± 1.3 days). These experiments suggest that TGE in C. elegans has positive effects on life span and neuronal function, associated with mildly increased ROS-formation. From the perspective of metabolic memory, hormetic effects outweighed the detrimental effects of a HG environment.
- 14 January 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 160
Open AccessProtective Effects of Transient Glucose Exposure in Adult C. elegans
C. elegans are used to study molecular pathways, linking high glucose levels (HG) to diabetic complications. Persistent exposure of C. elegans to a HG environment induces the mitochondrial formation of reactive oxygen species (ROS) and advanced glycation endproducts (AGEs), leading to neuronal damage and decreased lifespan. Studies suggest that transient high glucose exposure (TGE) exerts different effects than persistent exposure. Thus, the effects of TGE on ROS, AGE-formation and life span were studied in C. elegans. Four-day TGE (400 mM) as compared to controls (0mM) showed a persistent increase of ROS (4-days 286 ± 40 RLUs vs. control 187 ± 23 RLUs) without increased formation of AGEs. TGE increased body motility (1-day 0.14 ± 0.02; 4-days 0.15 ± 0.01; 6-days 0.16 ± 0.02 vs. control 0.10 ± 0.02 in mm/s), and bending angle (1-day 17.7 ± 1.55; 3-days 18.7 ± 1.39; 6-days 20.3 ± 0.61 vs. control 15.3 ± 1.63 in degree/s) as signs of neuronal damage. Lifespan was increased by 27% (21 ± 2.4 days) after one-day TGE, 34% (22 ± 1.2 days) after four-days TGE, and 26% (21 ± 1.4 days) after six-days TGE vs. control (16 ± 1.3 days). These experiments suggest that TGE in C. elegans has positive effects on life span and neuronal function, associated with mildly increased ROS-formation. From the perspective of metabolic memory, hormetic effects outweighed the detrimental effects of a HG environment.
- 1 December 2020
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 16 (01) , 55-62
Versorgungssituation und Mortalität von Patienten in Deutschland innerhalb und außerhalb des DMP Typ-2-Diabetes: eine kritische Analyse
Zusammenfassung: Typ-2-Diabetes(T2 D)-Patienten weisen im Vergleich zur Normalbevölkerung eine erhöhte Sterblichkeit auf. Ein Teil der Patienten ist mit dem Ziel einer besseren Versorgung in das nationale „Disease-Management-Programm Diabetes“ (DMP) Typ-2-Diabetes eingeschlossen. In dieser Arbeit werden Mortalitätsdaten von T2D-Patienten aus der Routineversorgung mit Mortalitätsdaten der Allgemeinbevölkerung und von T2D-Patienten aus verschiedenen Studienkollektiven verglichen. Die Sterblichkeit der deutschen T2D-Patienten insgesamt ist etwa 3,1-fach höher als in der Allgemeinbevölkerung. Die Sterblichkeit von deutschen T2D-Patienten innerhalb des DMP ist 2,4-fach höher. Inwieweit sich dieser Mortalitätsunterschied durch einen Selektionsbias oder durch die Teilnahme am DMP selbst erklären lässt, ist mit den verfügbaren Daten nicht eindeutig zu beantworten. Die Tatsache aber, dass im Vergleich dazu das Sterblichkeitsrisiko innerhalb kontrollierter T2D-Interventionsstudien trotz zusätzlicher kardiovaskulärer Komorbidität nochmals niedriger ist, gibt einen wichtigen Hinweis darauf, dass die kardiovaskuläre Pathophysiologie im bisherigen DMP nicht ausreichend berücksichtigt wird und dieser Tatbestand ein wichtiges Verbesserungspotenzial für eine Optimierung des DMP darstellt.
- 1 December 2020
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 16 (01) , 55-62
Versorgungssituation und Mortalität von Patienten in Deutschland innerhalb und außerhalb des DMP Typ-2-Diabetes: eine kritische Analyse
Zusammenfassung: Typ-2-Diabetes(T2 D)-Patienten weisen im Vergleich zur Normalbevölkerung eine erhöhte Sterblichkeit auf. Ein Teil der Patienten ist mit dem Ziel einer besseren Versorgung in das nationale „Disease-Management-Programm Diabetes“ (DMP) Typ-2-Diabetes eingeschlossen. In dieser Arbeit werden Mortalitätsdaten von T2D-Patienten aus der Routineversorgung mit Mortalitätsdaten der Allgemeinbevölkerung und von T2D-Patienten aus verschiedenen Studienkollektiven verglichen. Die Sterblichkeit der deutschen T2D-Patienten insgesamt ist etwa 3,1-fach höher als in der Allgemeinbevölkerung. Die Sterblichkeit von deutschen T2D-Patienten innerhalb des DMP ist 2,4-fach höher. Inwieweit sich dieser Mortalitätsunterschied durch einen Selektionsbias oder durch die Teilnahme am DMP selbst erklären lässt, ist mit den verfügbaren Daten nicht eindeutig zu beantworten. Die Tatsache aber, dass im Vergleich dazu das Sterblichkeitsrisiko innerhalb kontrollierter T2D-Interventionsstudien trotz zusätzlicher kardiovaskulärer Komorbidität nochmals niedriger ist, gibt einen wichtigen Hinweis darauf, dass die kardiovaskuläre Pathophysiologie im bisherigen DMP nicht ausreichend berücksichtigt wird und dieser Tatbestand ein wichtiges Verbesserungspotenzial für eine Optimierung des DMP darstellt.
- 12 June 2020
- Published by Wiley in Clinical Obesity
- Vol. 10 (5) , e12383
Impaired dexamethasone resorption in two patients with pseudo‐Cushing after bariatric surgery: Implications for immunosuppressive treatment
Summary: Two cases of middle‐aged female patients treated by gastric bypass surgery for weight loss presented to our clinic for a follow‐up examination 3‐6 months after the surgical procedure (a mini gastric bypass and a modified single anastomosis sleeve‐ileostomy). In both patients increased ACTH levels and either high serum cortisol or an increased urinary cortisol excretion was apparent and triggered further endocrine testing. Serum cortisol could not be suppressed adequately by 2 and 4 mg dexamethasone in the standardized oral overnight suppression test while midnight salivary cortisol dropped well below the desired cut‐off. This led to the hypothesis of an impaired dexamethasone resorption and could be further substantiated by suppression of serum cortisol below the cut‐off by an intravenous dexamethasone application. The data presented point to an impairment of enteral synthetic corticosteroid resorption in patients after gastric bypass surgery and could be of importance for individuals in need for immunosuppressive treatment. In view of the growing number of bariatric procedures, pharmacokinetics of corticosteroids and other drugs should be tested in clinical trials.
- 12 June 2020
- Published by Wiley in Clinical Obesity
- Vol. 10 (5) , e12383
Impaired dexamethasone resorption in two patients with pseudo‐Cushing after bariatric surgery: Implications for immunosuppressive treatment
Summary: Two cases of middle‐aged female patients treated by gastric bypass surgery for weight loss presented to our clinic for a follow‐up examination 3‐6 months after the surgical procedure (a mini gastric bypass and a modified single anastomosis sleeve‐ileostomy). In both patients increased ACTH levels and either high serum cortisol or an increased urinary cortisol excretion was apparent and triggered further endocrine testing. Serum cortisol could not be suppressed adequately by 2 and 4 mg dexamethasone in the standardized oral overnight suppression test while midnight salivary cortisol dropped well below the desired cut‐off. This led to the hypothesis of an impaired dexamethasone resorption and could be further substantiated by suppression of serum cortisol below the cut‐off by an intravenous dexamethasone application. The data presented point to an impairment of enteral synthetic corticosteroid resorption in patients after gastric bypass surgery and could be of importance for individuals in need for immunosuppressive treatment. In view of the growing number of bariatric procedures, pharmacokinetics of corticosteroids and other drugs should be tested in clinical trials.
- 1 August 2016
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 8 (4) , 526-532
Neuroprotection and antioxidative effects of Sijunzi Tang Decoction in the nematode Caenorhabditis elegans
- 1 August 2016
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 8 (4) , 526-532
Neuroprotection and antioxidative effects of Sijunzi Tang Decoction in the nematode Caenorhabditis elegans
- 6 January 2010
- Published by Springer Nature in Diabetologia
- Vol. 53 (3) , 403-405
Oxidative stress and glucose metabolism—is there a need to revisit effects of insulin treatment?
- 6 January 2010
- Published by Springer Nature in Diabetologia
- Vol. 53 (3) , 403-405
Oxidative stress and glucose metabolism—is there a need to revisit effects of insulin treatment?
- Open Access
- 1 January 2010
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 9 (1) , 48
Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.
- 1 January 2010
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 9 (1) , 48
Open AccessAssociations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.
- 1 June 2009
- Published by Elsevier in Atherosclerosis
- Vol. 206 (1) , 38-39
Retinol-binding protein 4 & atherosclerosis: Risk factor or innocent bystander?
- 1 June 2009
- Published by Elsevier in Atherosclerosis
- Vol. 206 (1) , 38-39
Retinol-binding protein 4 & atherosclerosis: Risk factor or innocent bystander?
- Open Access
- 1 March 2009
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 10 (2) , 413-419
External Electric Muscle Stimulation Improves Burning Sensations and Sleeping Disturbances in Patients with Type 2 Diabetes and Symptomatic Neuropathy
Objective. External muscle stimulation (EMS) of the thighs was previously shown to have beneficial effects in a pilot study on painful diabetic neuro
- 1 March 2009
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 10 (2) , 413-419
Open AccessExternal Electric Muscle Stimulation Improves Burning Sensations and Sleeping Disturbances in Patients with Type 2 Diabetes and Symptomatic Neuropathy
Objective. External muscle stimulation (EMS) of the thighs was previously shown to have beneficial effects in a pilot study on painful diabetic neuro
- 12 January 2009
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 41 (04) , 308-313
The −174G>C IL-6 Gene Promoter Polymorphism and Diabetic Microvascular Complications
This study examined a possible association of the G>C polymorphism at nucleotide −174 in the promoter region of the interleukin-6 (IL-6) gene (rs1800795) with the prevalence of diabetic complications in 235 patients with type 1 and 498 patients with type 2 diabetes. Genotyping was performed using polymerase chain reaction (PCR) and subsequent cleavage by Nla III restriction endonuclease. Analyzing all diabetic patients together demonstrated that 301 patients (41.1%) carried the GG genotype, 114 (15.6%) the CC genotype, and 318 (43.3%) were heterozygous for the GC genotype. However, there was no correlation of any of the genotypes with the prevalence of diabetic nephropathy or diabetic neuropathy, but subjects with the CC genotype had a significantly higher prevalence of diabetic retinopathy compared to patients with the GC and GG genotype (p=0.016). This association was mainly lost when a logistic regression model was adjusted for diabetes duration (p=0.07). Consistently, a weak but not significant association of the polymorphism with diabetic retinopathy was observed when type 1 and type 2 diabetic patients were analyzed separately (patients with type 1 diabetes: p=0.12; patients with type 2 diabetes: p=0.09). Analogically, no association of the polymorphism was found for diabetic nephropathy or diabetic neuropathy in these groups. In conclusion these data suggest no major influence of the −174G>C variant in the promoter region of the IL-6 gene on the development of microvascular complications in patients with diabetes.
- 12 January 2009
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 41 (04) , 308-313
The −174G>C IL-6 Gene Promoter Polymorphism and Diabetic Microvascular Complications
This study examined a possible association of the G>C polymorphism at nucleotide −174 in the promoter region of the interleukin-6 (IL-6) gene (rs1800795) with the prevalence of diabetic complications in 235 patients with type 1 and 498 patients with type 2 diabetes. Genotyping was performed using polymerase chain reaction (PCR) and subsequent cleavage by Nla III restriction endonuclease. Analyzing all diabetic patients together demonstrated that 301 patients (41.1%) carried the GG genotype, 114 (15.6%) the CC genotype, and 318 (43.3%) were heterozygous for the GC genotype. However, there was no correlation of any of the genotypes with the prevalence of diabetic nephropathy or diabetic neuropathy, but subjects with the CC genotype had a significantly higher prevalence of diabetic retinopathy compared to patients with the GC and GG genotype (p=0.016). This association was mainly lost when a logistic regression model was adjusted for diabetes duration (p=0.07). Consistently, a weak but not significant association of the polymorphism with diabetic retinopathy was observed when type 1 and type 2 diabetic patients were analyzed separately (patients with type 1 diabetes: p=0.12; patients with type 2 diabetes: p=0.09). Analogically, no association of the polymorphism was found for diabetic nephropathy or diabetic neuropathy in these groups. In conclusion these data suggest no major influence of the −174G>C variant in the promoter region of the IL-6 gene on the development of microvascular complications in patients with diabetes.
- Open Access
- 29 February 2008
- Published by Springer Nature in Molecular Medicine
- Vol. 14 (5-6) , 301-308
Insulin Stimulates the Clonogenic Potential of Angiogenic Endothelial Progenitor Cells by IGF-1 Receptor-Dependent Signaling
Endothelial progenitor cells (EPCs) have been shown to be involved in vascular regeneration and angiogenesis in experimental diabetes. Because insulin therapy mobilizes circulating progenitor cells, we studied the effects of insulin on outgrowth of EPCs from peripheral blood mononuclear cells of healthy volunteers and patients with type 2 diabetes. Insulin increased the formation of EPC colony-forming units in a dose-dependent manner, half-maximal at 1.5 nM and peaking at 15 nM. Inhibiting the insulin receptor with neutralizing antibodies or antisense oligonucleotides had no effect on EPC outgrowth.(1) In contrast, targeting the human insulin-like growth factor 1 (IGF-1) receptor with neutralizing antibodies significantly suppressed insulin-induced outgrowth of EPCs from both healthy controls and patients with type 2 diabetes. This IGF-1 receptor-mediated insulin effect on EPC growth was at least in part dependent on MAP kinases(2) and was abrogated when extracellular signal-regulated kinase 1/2 (Erk1/2) and protein kinase 38 (p38) activity was inhibited. To study the functional relevance of the observed insulin effects, we studied EPC-induced tube formation of bovine endothelial cells in vitro. Insulin-stimulated EPCs incorporated into the endothelial tubes and markedly enhanced tube formation. In conclusion, this is the first study showing an insulin-mediated activation of the IGF-1 receptor leading to an increased clonogenic and angiogenic potential of EPCs in vitro.
- 29 February 2008
- Published by Springer Nature in Molecular Medicine
- Vol. 14 (5-6) , 301-308
Open AccessInsulin Stimulates the Clonogenic Potential of Angiogenic Endothelial Progenitor Cells by IGF-1 Receptor-Dependent Signaling
Endothelial progenitor cells (EPCs) have been shown to be involved in vascular regeneration and angiogenesis in experimental diabetes. Because insulin therapy mobilizes circulating progenitor cells, we studied the effects of insulin on outgrowth of EPCs from peripheral blood mononuclear cells of healthy volunteers and patients with type 2 diabetes. Insulin increased the formation of EPC colony-forming units in a dose-dependent manner, half-maximal at 1.5 nM and peaking at 15 nM. Inhibiting the insulin receptor with neutralizing antibodies or antisense oligonucleotides had no effect on EPC outgrowth.(1) In contrast, targeting the human insulin-like growth factor 1 (IGF-1) receptor with neutralizing antibodies significantly suppressed insulin-induced outgrowth of EPCs from both healthy controls and patients with type 2 diabetes. This IGF-1 receptor-mediated insulin effect on EPC growth was at least in part dependent on MAP kinases(2) and was abrogated when extracellular signal-regulated kinase 1/2 (Erk1/2) and protein kinase 38 (p38) activity was inhibited. To study the functional relevance of the observed insulin effects, we studied EPC-induced tube formation of bovine endothelial cells in vitro. Insulin-stimulated EPCs incorporated into the endothelial tubes and markedly enhanced tube formation. In conclusion, this is the first study showing an insulin-mediated activation of the IGF-1 receptor leading to an increased clonogenic and angiogenic potential of EPCs in vitro.